kabutan

Solasia Pharma K.K.(4597) Summary

4597
TSE Growth
Solasia Pharma K.K.
28
JPY
-1
(-3.45%)
Jan 29, 1:36 pm JST
0.18
USD
Jan 28, 11:36 pm EST
Result
PTS
outside of trading hours
28.4
Jan 29, 1:36 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.11
Yield
ー%
Margin Trading Ratio
2.75
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
28 JPY 0.18 USD
Previous Close Jan 28
29 JPY 0.19 USD
High Jan 29, 9:03 am
29 JPY 0.18 USD
Low Jan 29, 9:00 am
28 JPY 0.18 USD
Volume
24,851,800
Trading Value
0.70B JPY 4.55M USD
VWAP
28.0 JPY 0.18 USD
Minimum Trading Value
2,800 JPY 18 USD
Market Cap
7.38B JPY 0.05B USD
Number of Trades
54
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
356
1-Year High Jun 27, 2025
2,772
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 1,748,500 21,900,000 12.53
Jan 16, 2026 1,697,200 21,308,900 12.56
Jan 9, 2026 1,744,100 23,080,400 13.23
Dec 26, 2025 1,370,700 22,931,200 16.73
Dec 19, 2025 2,362,900 24,916,900 10.55
Company Profile
Solasia Pharma K.K. is a biopharmaceutical venture company focused on cancer and malignant tumor drug discovery. The company engages in the development of pharmaceuticals and medical devices, with a primary focus on clinical development.
Sector
Pharmaceuticals
Solasia Pharma K.K. operates as a biopharmaceutical venture company specializing in the oncology field, developing both pharmaceuticals and medical devices. The company primarily concentrates on clinical development, introducing promising new drug candidates and conducting trials in Japan and other Asian countries. With multiple development pipelines, Solasia focuses on treatments for malignant tumors and supportive care medications. Their product portfolio includes darinaparsin for peripheral T-cell lymphoma, a transdermal granisetron preparation for preventing chemotherapy-induced nausea and vomiting, and a medical device aimed at alleviating pain from oral mucositis. The company's business model encompasses the entire process from clinical development to regulatory submission and out-licensing of marketing rights. Solasia aims to generate revenue through out-licensing to pharmaceutical companies, which includes sales revenue, milestone payments, and royalty income.